



The TIMI Trials

ANTHEM-TIMI 32

OBJECTIVE: To assess the efficacy and safety of anticoagulation with rNAPc2 in non-ST segment elevation acute coronary syndrome patients managed with an early invasive strategy.

1. Giugliano RP, Wiviott SD, Stone PH, Simon DI, Schweiger MJ, Bouchard A, Leesar MA, Goulder MA, Deitcher SR, McCabe CH, Braunwald E. Recombinant nematode anticoagulant protein C2 (rNAPc2) in patients with non-ST-elevation acute coronary syndrome – the ANTHEM - TIMI 32 trial. *J Am Coll Cardiol* 2007;49:2398-407.